Mesoblast Ltd Files Form 6-K with SEC
Ticker: MEOBF · Form: 6-K · Filed: Jul 25, 2024 · CIK: 1345099
| Field | Detail |
|---|---|
| Company | Mesoblast LTD (MEOBF) |
| Form Type | 6-K |
| Filed Date | Jul 25, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
MESO filed a 6-K on July 23rd, just a heads-up for investors.
AI Summary
On July 23, 2024, Mesoblast Limited announced a new release filed with the Australian Securities Exchange. This report is filed as a Form 6-K with the SEC, indicating it's a report from a foreign private issuer.
Why It Matters
This filing signifies Mesoblast Limited's compliance with SEC reporting requirements for foreign private issuers, providing updates to the market.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain significant new financial or operational information that would inherently increase risk.
Key Players & Entities
- Mesoblast Limited (company) — Registrant
- Silviu Itescu (person) — Chief Executive Officer and Executive Director
- Australian Securities Exchange (company) — Exchange where announcement was filed
- July 23, 2024 (date) — Date of announcement
FAQ
What type of filing is this Form 6-K?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Who is the Chief Executive Officer of Mesoblast Limited?
Silviu Itescu is the Chief Executive Officer and Executive Director of Mesoblast Limited.
Where is Mesoblast Limited's principal executive office located?
Mesoblast Limited's principal executive office is located at Level 38, 55 Collins Street, Melbourne 3000, Australia.
What is the Commission File Number for Mesoblast Limited?
The Commission File Number for Mesoblast Limited is 001-37626.
What is the SIC code for Mesoblast Limited?
The Standard Industrial Classification (SIC) code for Mesoblast Limited is 2836, which corresponds to Biological Products (no diagnostic substances).
Filing Stats: 212 words · 1 min read · ~1 pages · Grade level 17.5 · Accepted 2024-07-24 21:33:02
Filing Documents
- a2024-07x24ryoncilfdaaccep.htm (6-K) — 20KB
- exhibit991.htm (EX-99.1) — 14KB
- exhibit991001.jpg (GRAPHIC) — 274KB
- exhibit991002.jpg (GRAPHIC) — 289KB
- exhibit991003.jpg (GRAPHIC) — 273KB
- 0001345099-24-000059.txt ( ) — 1187KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized. Mesoblast Limited s Niva Sivakumar Niva Sivakumar Company Secretary Dated July 24, 2024 INDEX TO EXHIBITS Item 99.1 Press release of Mesoblast Ltd, dated July 23, 2024.